DK3323814T3 - (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepan-2-carboxamider som dipeptidylpeptidase i-hæmmere - Google Patents

(2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepan-2-carboxamider som dipeptidylpeptidase i-hæmmere Download PDF

Info

Publication number: DK3323814T3
Authority: DK; Denmark
Prior art keywords: dipeptidylpeptidase; oxazepan; carboxamides; phenylethyl; cyano
Prior art date: 2014-01-24

Application number

DK17195612.1T

Other languages

English (en)

Inventor

Hans Roland LÖNN

Stephen Connolly

Steven Swallow

Staffan Po Karlsson

Carl-Johan Aurell

John Fritiof Pontén

Kevin James Doyle

Graham Peter Jones

David Wyn Watson

Jaqueline Anne Macritchie

Nicholas John Palmer

De Poël Amanda Jane Van

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-01-24

Filing date

2015-01-23

Publication date

2020-08-03

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52432834&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3323814(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-01-23 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2020-08-03 Application granted granted Critical

2020-08-03 Publication of DK3323814T3 publication Critical patent/DK3323814T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/10—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Epoxy Compounds (AREA)
Hydrogenated Pyridines (AREA)

DK17195612.1T 2014-01-24 2015-01-23 (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepan-2-carboxamider som dipeptidylpeptidase i-hæmmere DK3323814T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201461931090P	2014-01-24	2014-01-24
EP15701577.7A EP3097086B1 (en)	2014-01-24	2015-01-23	(2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors

Publications (1)

Publication Number	Publication Date
DK3323814T3 true DK3323814T3 (da)	2020-08-03

Family

ID=52432834

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
DK17195612.1T DK3323814T3 (da)	2014-01-24	2015-01-23	(2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepan-2-carboxamider som dipeptidylpeptidase i-hæmmere
DK20173862.2T DK3744714T3 (da)	2014-01-24	2015-01-23	(2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepan-2-carboxamider som dipeptidylpeptidase i-hæmmere
DK15701577.7T DK3097086T3 (da)	2014-01-24	2015-01-23	(2s)-n-[(1s)-1-cyan-2-phenylethyl]-1,4-oxazepan-2-carboxamider som dipeptidyl-peptidase i-hæmmere

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
DK20173862.2T DK3744714T3 (da)	2014-01-24	2015-01-23	(2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepan-2-carboxamider som dipeptidylpeptidase i-hæmmere
DK15701577.7T DK3097086T3 (da)	2014-01-24	2015-01-23	(2s)-n-[(1s)-1-cyan-2-phenylethyl]-1,4-oxazepan-2-carboxamider som dipeptidyl-peptidase i-hæmmere

Country Status (39)

Country	Link
US (18)	US9522894B2 (da)
EP (4)	EP3097086B1 (da)
JP (7)	JP6469711B2 (da)
KR (1)	KR102417684B1 (da)
CN (2)	CN110483492B (da)
AP (1)	AP2016009322A0 (da)
AR (1)	AR099177A1 (da)
AU (4)	AU2015208932C1 (da)
BR (1)	BR112016016224B1 (da)
CA (1)	CA2935625C (da)
CL (1)	CL2016001889A1 (da)
CR (1)	CR20160327A (da)
CY (2)	CY1120049T1 (da)
DK (3)	DK3323814T3 (da)
DO (1)	DOP2016000175A (da)
EA (1)	EA032794B1 (da)
ES (3)	ES2808060T3 (da)
FI (1)	FI3744714T3 (da)
HK (1)	HK1225730B (da)
HR (3)	HRP20180116T1 (da)
HU (3)	HUE038274T2 (da)
IL (3)	IL246614B (da)
LT (3)	LT3744714T (da)
MX (1)	MX368840B (da)
MY (1)	MY194850A (da)
NO (1)	NO2699580T3 (da)
NZ (2)	NZ722063A (da)
PE (1)	PE20161218A1 (da)
PH (1)	PH12016501439B1 (da)
PL (3)	PL3744714T3 (da)
PT (3)	PT3744714T (da)
RS (3)	RS56919B1 (da)
SG (2)	SG10201701056QA (da)
SI (3)	SI3323814T1 (da)
SM (3)	SMT201800058T1 (da)
TW (1)	TWI690517B (da)
UY (1)	UY35963A (da)
WO (1)	WO2015110826A1 (da)
ZA (2)	ZA201605856B (da)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NO2699580T3 (da)	2014-01-24	2018-02-24
KR20190035781A (ko) *	2016-07-29	2019-04-03	인스메드 인코포레이티드	기관지확장증을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카르복스아미드
EP3749326A4 (en) *	2018-02-07	2021-11-03	Insmed Incorporated	CERTAIN (2S) -N - [(1S) -1-CYANO-2-PHENYLETHYL] -1,4-OXAZEPAN-2-CARBOXAMIDE FOR THE TREATMENT OF VASCULITIDES ASSOCIATED WITH ANCA
PL3758708T3 (pl)	2018-03-01	2025-03-31	Astrazeneca Ab	Kompozycje farmaceutyczne zawierające (2s)-{(1s)-1-cyjano-2-[4-(3-metylo-2-okso-2,3-dihydro-1,3-benzoksazol-5-ilo)fenylo]etylo}-1,4-oksazepano-2-karboksyamid
JP2021530513A (ja) *	2018-07-17	2021-11-11	インスメッドインコーポレイテッド	炎症性腸疾患を処置するための特定の（２ｓ）−ｎ−［（１ｓ）−１−シアノ−２−フェニルエチル］−１，４−オキサゼパン−２−カルボキサミド
EP3823627A4 (en) *	2018-07-17	2022-04-20	Insmed Incorporated	CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES FOR THE TREATMENT OF LUPUS ENEHROPATHY
CN111689923B (zh) *	2019-03-12	2022-11-08	中国科学院上海药物研究所	一个具有逆转肿瘤多药耐药活性的环脂肽化合物、其制备方法及用途
CN114599367A (zh) *	2019-10-23	2022-06-07	株式会社钟根堂	用于预防或治疗慢性阻塞性肺病(copd)的组合物
JP2023535332A (ja) *	2020-07-20	2023-08-17	インスメッドインコーポレイテッド	好中球セリンプロテアーゼを抽出するおよびジペプチジルペプチダーゼ１媒介性病態を治療するための方法
EP4497473A3 (en)	2020-08-26	2025-04-23	Haisco Pharmaceuticals Pte. Ltd.	Nitrile derivative that acts as inhibitor of dipeptidyl peptidase 1 and use thereof
US11351149B2 (en)	2020-09-03	2022-06-07	Pfizer Inc.	Nitrile-containing antiviral compounds
CN114159446A (zh) *	2020-09-11	2022-03-11	中国科学院上海营养与健康研究所	组织蛋白酶c抑制剂在治疗肿瘤转移中的应用
JP2023551488A (ja) *	2020-12-04	2023-12-08	瑞石生物医薬有限公司	カテプシンｃの小分子阻害剤及びその医薬的使用
CN114591315A (zh) *	2020-12-04	2022-06-07	瑞石生物医药有限公司	一种组织蛋白酶c小分子抑制剂
WO2022140516A1 (en) *	2020-12-22	2022-06-30	Insmed Incorporated	Certain (25)-iv-[(ls')~ i-c yan0-2-phenylethyl·]- 1,4-oxazepane-2- carboxamides for treating behcet's disease
EP4289827A4 (en) *	2021-02-05	2025-01-22	Medshine Discovery Inc.	CONDENSED RING DERIVATIVES CONTAINING 1,4-OXAZEPANE
CA3215375A1 (en) *	2021-04-29	2022-11-03	Insmed Incorporated	Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating cystic fibrosis
CN118159525A (zh) *	2021-10-29	2024-06-07	英斯梅德股份有限公司	用于治疗慢性鼻窦炎的特定n-(1-氰基-2-苯乙基)-1,4-氧杂氮杂环庚烷-2-甲酰胺
CN115925696A (zh) *	2021-10-29	2023-04-07	瑞石生物医药有限公司	一种1-氰基-2-苯基乙基甲酰胺衍生物及其用途
CN116332937A (zh) *	2021-12-23	2023-06-27	杭州邦顺制药有限公司	二肽基肽酶ⅰ抑制剂及其用途
US20250101011A1 (en) *	2022-01-11	2025-03-27	Shanghai Yidian Pharmaceutical Technology Development Co., Ltd	Peptidyl nitrile compound and use thereof
IL314769A (en) *	2022-02-16	2024-10-01	Insmed Inc	Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating hidradenitis suppurativa
JP2025508792A (ja) *	2022-02-22	2025-04-10	ハイスコファーマスーティカルプライベートリミテッド	ジペプチジルペプチダーゼ阻害化合物の塩及び結晶形態
JP2025506307A (ja) *	2022-02-22	2025-03-07	ハイスコファーマスーティカルプライベートリミテッド	含窒素複素環化合物の調製方法
CA3244653A1 (en) *	2022-02-22	2025-01-24	Haisco Pharmaceuticals Pte Ltd	DIPEPTIDYL PEPTIDASE 1 INHIBITOR POLYMORPH, ITS PREPARATION PROCESS AND ITS USE
CN114644562B (zh) *	2022-04-29	2023-08-22	常州大学	具有红移荧光发射的有机小分子荧光化合物、制备方法及应用
WO2023236879A1 (zh)	2022-06-07	2023-12-14	瑞石生物医药有限公司	苯并[c]色满化合物的多晶型及其制备方法和用途
JP2025518345A (ja) *	2022-06-07	2025-06-12	瑞石生物医薬有限公司	ベンゾ［ｃ］クロマン化合物の薬学的に許容される塩、ならびに薬学的に許容される塩の多形及び使用
AU2023296161A1 (en)	2022-06-13	2025-01-02	Alivexis, Inc.	Azacycloalkyl carbonyl cyclic amine compound
US20250250232A1 (en)	2022-07-06	2025-08-07	Chiesi Farmaceutici S.P.A.	Azetidine derivatives and use thereof as dipeptidyl peptidase 1 inhibitors
EP4602043A1 (en)	2022-10-14	2025-08-20	Genesis Therapeutics, Inc.	4h-pyrido[1,2-a]pyrimidin-4-one derivatives for treating cancer
WO2024088307A1 (zh) *	2022-10-26	2024-05-02	上海壹迪生物技术有限公司	一种新型肽基腈类化合物及其应用
CN115785083A (zh) *	2022-12-27	2023-03-14	瑞石生物医药有限公司	一种组织蛋白酶c小分子抑制剂及其制备方法
EP4646265A1 (en)	2023-01-06	2025-11-12	Insmed Incorporated	Novel, reversible dpp1 inhibitors and uses thereof
CN120693326A (zh) *	2023-02-15	2025-09-23	英斯梅德股份有限公司	某些1，4-氧杂氮杂环庚烷-2-甲酰胺作为dpp1抑制剂的用途
CN120957728A (zh) *	2023-03-23	2025-11-14	海思科医药集团股份有限公司	一种二肽基肽酶小分子抑制剂的药物组合物
WO2025059526A1 (en) *	2023-09-15	2025-03-20	Insmed Incorporated	Dipeptidyl peptidase 1 inhibitors and uses thereof
USD1099133S1 (en) *	2024-02-01	2025-10-21	Apple Inc.	Display screen or portion thereof showing a graphical user interface
WO2025214073A1 (en) *	2024-04-12	2025-10-16	Insmed Incorporated	Dipeptidyl peptidase 1 inhibitors and uses thereof

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2782151B2 (ja)	1993-07-16	1998-07-30	博吉田	衝撃吸収柵用の端ストッパ
US6297239B1 (en)	1997-10-08	2001-10-02	Merck & Co., Inc.	Inhibitors of prenyl-protein transferase
US6566372B1 (en)	1999-08-27	2003-05-20	Ligand Pharmaceuticals Incorporated	Bicyclic androgen and progesterone receptor modulator compounds and methods
US6462076B2 (en)	2000-06-14	2002-10-08	Hoffmann-La Roche Inc.	Beta-amino acid nitrile derivatives as cathepsin K inhibitors
EP1317555B1 (en)	2000-09-08	2007-11-14	Prozymex A/S	Rat cathepsin, dipeptidyl peptidase i (dppi): crystal structure, inhibitors and its uses
AU2001294196B2 (en) *	2000-10-06	2005-11-17	Tanabe Seiyaku Co., Ltd.	Nitrogenous five-membered ring compounds
EP1217000A1 (en)	2000-12-23	2002-06-26	Aventis Pharma Deutschland GmbH	Inhibitors of factor Xa and factor VIIa
AU2002352126A1 (en)	2001-12-04	2003-06-17	F. Hoffmann-La Roche Ag	Substituted 2-amino-cycloalkanecarboxamides and their use as cysteine protease inhibitors
US20040253311A1 (en)	2002-12-18	2004-12-16	Roger Berlin	Multi-layer tablet comprising non-steroidal anti-inflammatory drugs, decongestants and non-sedating antihist amines
WO2004076434A1 (en)	2003-02-28	2004-09-10	Aic	Dipeptidyl peptidase inhibitors
US7893096B2 (en)	2003-03-28	2011-02-22	Novartis Vaccines And Diagnostics, Inc.	Use of small molecule compounds for immunopotentiation
US20070155803A1 (en)	2003-05-30	2007-07-05	Prozymex A/S	Protease inhibitors
JP2006527704A (ja) *	2003-06-18	2006-12-07	プロザイメックス・アクティーゼルスカブ	プロテアーゼ阻害剤
EP3372614B1 (en)	2004-04-07	2022-06-08	Rinat Neuroscience Corp.	Methods for treating bone cancer pain by administering a nerve growth factor antagonist
WO2005106012A2 (en)	2004-04-28	2005-11-10	Bayer Healthcare Ag	Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 1 (dpp1)
US7618981B2 (en)	2004-05-06	2009-11-17	Cytokinetics, Inc.	Imidazopyridinyl-benzamide anti-cancer agents
SE0401657D0 (sv)	2004-06-24	2004-06-24	Astrazeneca Ab	Chemical compounds
EA014443B1 (ru)	2004-06-29	2010-12-30	Никомед Данмарк Апс	Фармацевтическая композиция (варианты) и способ ее производства
AU2005274852B2 (en)	2004-07-19	2011-12-08	The Johns Hopkins University	FLT3 inhibitors for immune suppression
SG166775A1 (en)	2005-02-18	2010-12-29	Abraxis Bioscience Llc	Combinations and modes of administration of therapeutic agents and combination therapy
AU2006265835B2 (en)	2005-06-30	2012-05-03	Amgen Inc.	Bis-aryl kinase inhibitors and their use in the treatment of inflammation, angiogenesis and cancer
CA2680177A1 (en)	2007-03-07	2008-09-12	Alantos Pharmaceuticals Holding, Inc.	Metalloprotease inhibitors containing a heterocyclic moiety
WO2009026701A1 (en)	2007-08-29	2009-03-05	Methylgene Inc.	Sirtuin inhibitors
BRPI0817311A2 (pt)	2007-09-25	2015-03-17	Novartis Ag	Tratamento de doenças pulmonares com medicamentos em aerossol tais como a vancomicina
BRPI0820665A2 (pt) *	2007-12-12	2018-05-29	Astrazeneca Ab	compostos de peptidil nitrilas, processos para fabricação dos mesmos, composição farmacêutica, combinação e uso de ditos compostos
US9315449B2 (en)	2008-05-15	2016-04-19	Duke University	Substituted pyrazoles as heat shock transcription factor activators
PE20100252A1 (es)	2008-06-06	2010-04-12	Boehringer Ingelheim Int	Nuevas formulaciones farmaceuticas solidas que comprenden dimaleato de 4-[(3-cloro-4-fluorofenil) amino]-6-{[4-(n,n-dimetilamino)-1-oxo-2-buten-1-il] amino}-7-((s)-tetrahidrofuran-3-iloxi)-quinazolina
NZ593937A (en)	2008-12-08	2014-05-30	Vm Pharma Llc	Compositions of protein receptor tyrosine kinase inhibitors
AU2010231962B2 (en)	2009-04-01	2015-05-21	Bial - Portela & Ca., S.A.	Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making the same
BRPI1015540A2 (pt) *	2009-05-07	2019-09-24	Astrazeneca Ab	''composto de 1-cianoetil-heterociclilcarboxamida substituídos 750''
WO2010142985A1 (en) *	2009-06-10	2010-12-16	Astrazeneca Ab	Substituted n-[1-cyano-2-(phenyl)ethyl]piperidin-2-ylcarboxmide compounds 761
EP2555755B2 (en)	2010-04-07	2019-07-10	Vertex Pharmaceuticals Incorporated	Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof
WO2011154677A1 (en)	2010-06-09	2011-12-15	Astrazeneca Ab	Substituted n-[1-cyano-2-(phenyl)ethyl] 1-aminocycloalk-1-ylcarboxamide compounds - 760
IT1404036B1 (it)	2010-12-17	2013-11-08	Oto Melara Spa	Veicolo armato con struttura migliorata.
JP5931929B2 (ja)	2011-02-11	2016-06-08	グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙＤｅｖｅｌｏｐｍｅｎｔＬｉｍｉｔｅｄ	カテプシンｃ阻害剤
WO2012119941A1 (en)	2011-03-04	2012-09-13	Prozymex A/S	Peptidyl nitrilcompounds as peptidase inhibitors
US8999975B2 (en)	2011-09-19	2015-04-07	Boehringer Ingelheim International Gmbh	Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C
WO2013124026A1 (en)	2012-02-21	2013-08-29	Merck Patent Gmbh	8 - substituted 2 -amino - [1,2,4] triazolo [1, 5 -a] pyrazines as syk tryrosine kinase inhibitors and gcn2 serin kinase inhibitors
US9328118B2 (en)	2012-04-17	2016-05-03	Astellas Pharma Inc.	Nitrogen-containing bicyclic aromatic heterocyclic compound
WO2014091443A1 (en)	2012-12-13	2014-06-19	Glaxo Group Limited	Cathepsin c inhibitors for treating cystic fibrosis, non-cystic fibrosis bronchiectasis, and anca-associated vasculitis
EP2775304A1 (en)	2013-03-07	2014-09-10	Universitätsspital Basel	Methods for detecting inflammatory disorder
EP2970230B1 (en)	2013-03-14	2019-05-22	Boehringer Ingelheim International GmbH	Substituted bicyclic 1-carboxylic-acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
DK2970283T3 (da)	2013-03-14	2021-01-25	Boehringer Ingelheim Int	Substituerede 2-aza-bicyclo[2.2.1]heptan-3-carboxylsyre-(benzyl-cyano-methyl)-amider som inhibitorer af cathepsin-c
US8871783B2 (en)	2013-03-14	2014-10-28	Boehringer Ingelheim International Gmbh	Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (cyano-methyl)-amides inhibitors of cathepsin C
US8877775B2 (en)	2013-03-14	2014-11-04	Boehringer Ingelheim International Gmbh	Substituted 2-aza-bicyclo[2.2.2]octane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin C
UY35400A (es)	2013-03-15	2014-10-31	Novartis Ag	Compuestos y composiciones para el tratamiento de enfermedades parasitarias
AU2014248455B2 (en)	2013-04-01	2018-12-06	Pulmatrix Operating Company, Inc.	Tiotropium dry powders
WO2015027039A1 (en)	2013-08-22	2015-02-26	Emory University	Devices and methods related to airway inflammation
WO2015032942A1 (en)	2013-09-09	2015-03-12	Prozymex A/S	N-substituted 3,3'-(biphenyl-4,4'-diyl)bis-2-aminopropanenitriles as dppi inhibitors
SG11201601150WA (en)	2013-09-09	2016-03-30	Prozymex As	Peptidyl nitril compounds as dipeptidyl peptidase i inhibitors
GB201400034D0 (en)	2014-01-02	2014-02-19	Astrazeneca Ab	Pharmaceutical Compositions comprising AZD9291
NO2699580T3 (da)	2014-01-24	2018-02-24
GB201402070D0 (en)	2014-02-07	2014-03-26	Galapagos Nv	Pharmaceutical compositions for the treatment of inflammatory disorders
JP6674903B2 (ja)	2014-04-10	2020-04-01	ノバルティスアーゲー	Ｓ１ｐ調節剤即時放出投与レジメン
EP3466432B1 (en)	2014-05-15	2020-07-08	Insmed Incorporated	Methods for treating pulmonary non-tuberculous mycobacterial infections
US9625460B2 (en)	2014-05-30	2017-04-18	Versitech Limited	Methods and compositions for use of neutrophil elastase and proteinase 3 as diagnostic biomarkers
WO2016016242A1 (en)	2014-08-01	2016-02-04	Boehringer Ingelheim International Gmbh	Substituted oxetanes and their use as inhibitors of cathepsin c
KR102510588B1 (ko)	2014-09-12	2023-03-17	베링거 인겔하임 인터내셔날 게엠베하	카텝신 c의 스피로사이클릭 억제제
CA2965566A1 (en)	2014-11-14	2016-05-19	Boehringer Ingelheim International Gmbh	Morpholine and 1,4-oxazepane amides as somatostatin receptor subtype 4 (sstr4) agonists
DK3265452T3 (en)	2015-03-05	2020-06-08	Neuprozyme Therapeutics ApS	Peptidyl nitril compounds as dipeptidyl peptidase i inhibitors
KR20190035781A (ko)	2016-07-29	2019-04-03	인스메드 인코포레이티드	기관지확장증을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카르복스아미드
EP3749326A4 (en)	2018-02-07	2021-11-03	Insmed Incorporated	CERTAIN (2S) -N - [(1S) -1-CYANO-2-PHENYLETHYL] -1,4-OXAZEPAN-2-CARBOXAMIDE FOR THE TREATMENT OF VASCULITIDES ASSOCIATED WITH ANCA
PL3758708T3 (pl)	2018-03-01	2025-03-31	Astrazeneca Ab	Kompozycje farmaceutyczne zawierające (2s)-{(1s)-1-cyjano-2-[4-(3-metylo-2-okso-2,3-dihydro-1,3-benzoksazol-5-ilo)fenylo]etylo}-1,4-oksazepano-2-karboksyamid
JP2021530513A (ja)	2018-07-17	2021-11-11	インスメッドインコーポレイテッド	炎症性腸疾患を処置するための特定の（２ｓ）−ｎ−［（１ｓ）−１−シアノ−２−フェニルエチル］−１，４−オキサゼパン−２−カルボキサミド
EP3823627A4 (en)	2018-07-17	2022-04-20	Insmed Incorporated	CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES FOR THE TREATMENT OF LUPUS ENEHROPATHY
JP7085073B2 (ja)	2019-04-17	2022-06-15	アゾーラセラピューティクス，インコーポレイテッド	炎症性皮膚疾患を処置するための局所組成物及び方法
AU2020289560A1 (en)	2019-06-05	2021-12-23	Emory University	Peptidomimetics for the treatment of coronavirus and picornavirus infections
WO2022140516A1 (en)	2020-12-22	2022-06-30	Insmed Incorporated	Certain (25)-iv-[(ls')~ i-c yan0-2-phenylethyl·]- 1,4-oxazepane-2- carboxamides for treating behcet's disease
CN112920124B (zh)	2021-01-29	2024-03-01	安徽医科大学	一种嘧啶-2,4-二胺类化合物及其制备方法与应用
WO2022232420A1 (en)	2021-04-29	2022-11-03	Insmed Incorporated	Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating cancer
CA3215375A1 (en)	2021-04-29	2022-11-03	Insmed Incorporated	Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating cystic fibrosis
CN118159525A (zh)	2021-10-29	2024-06-07	英斯梅德股份有限公司	用于治疗慢性鼻窦炎的特定n-(1-氰基-2-苯乙基)-1,4-氧杂氮杂环庚烷-2-甲酰胺
IL314769A (en)	2022-02-16	2024-10-01	Insmed Inc	Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating hidradenitis suppurativa

2012
- 2012-04-15 NO NO12774761A patent/NO2699580T3/no unknown
2015
- 2015-01-21 US US14/601,371 patent/US9522894B2/en active Active
- 2015-01-23 HU HUE15701577A patent/HUE038274T2/hu unknown
- 2015-01-23 AP AP2016009322A patent/AP2016009322A0/en unknown
- 2015-01-23 PL PL20173862.2T patent/PL3744714T3/pl unknown
- 2015-01-23 RS RS20180069A patent/RS56919B1/sr unknown
- 2015-01-23 PT PT201738622T patent/PT3744714T/pt unknown
- 2015-01-23 MY MYPI2016702657A patent/MY194850A/en unknown
- 2015-01-23 HR HRP20180116TT patent/HRP20180116T1/hr unknown
- 2015-01-23 UY UY0001035963A patent/UY35963A/es not_active Application Discontinuation
- 2015-01-23 ES ES17195612T patent/ES2808060T3/es active Active
- 2015-01-23 JP JP2016548068A patent/JP6469711B2/ja active Active
- 2015-01-23 EP EP15701577.7A patent/EP3097086B1/en active Active
- 2015-01-23 TW TW104102345A patent/TWI690517B/zh active
- 2015-01-23 NZ NZ722063A patent/NZ722063A/en unknown
- 2015-01-23 CN CN201910716882.4A patent/CN110483492B/zh active Active
- 2015-01-23 SM SM20180058T patent/SMT201800058T1/it unknown
- 2015-01-23 DK DK17195612.1T patent/DK3323814T3/da active
- 2015-01-23 SI SI201531287T patent/SI3323814T1/sl unknown
- 2015-01-23 EP EP25150988.1A patent/EP4548972A3/en active Pending
- 2015-01-23 DK DK20173862.2T patent/DK3744714T3/da active
- 2015-01-23 DK DK15701577.7T patent/DK3097086T3/da active
- 2015-01-23 PT PT171956121T patent/PT3323814T/pt unknown
- 2015-01-23 HK HK16114117.1A patent/HK1225730B/en unknown
- 2015-01-23 HR HRP20250302TT patent/HRP20250302T1/hr unknown
- 2015-01-23 EP EP20173862.2A patent/EP3744714B1/en active Active
- 2015-01-23 LT LTEP20173862.2T patent/LT3744714T/lt unknown
- 2015-01-23 CN CN201580005484.1A patent/CN105980367B/zh active Active
- 2015-01-23 LT LTEP17195612.1T patent/LT3323814T/lt unknown
- 2015-01-23 SG SG10201701056QA patent/SG10201701056QA/en unknown
- 2015-01-23 BR BR112016016224-2A patent/BR112016016224B1/pt active IP Right Grant
- 2015-01-23 EP EP17195612.1A patent/EP3323814B1/en active Active
- 2015-01-23 RS RS20200858A patent/RS60639B1/sr unknown
- 2015-01-23 SM SM20200433T patent/SMT202000433T1/it unknown
- 2015-01-23 RS RS20250323A patent/RS66709B1/sr unknown
- 2015-01-23 HU HUE17195612A patent/HUE052421T2/hu unknown
- 2015-01-23 ES ES20173862T patent/ES3018635T3/es active Active
- 2015-01-23 KR KR1020167022665A patent/KR102417684B1/ko active Active
- 2015-01-23 FI FIEP20173862.2T patent/FI3744714T3/fi active
- 2015-01-23 CR CR20160327A patent/CR20160327A/es unknown
- 2015-01-23 SG SG11201606052TA patent/SG11201606052TA/en unknown
- 2015-01-23 SM SM20250137T patent/SMT202500137T1/it unknown
- 2015-01-23 SI SI201532060T patent/SI3744714T1/sl unknown
- 2015-01-23 PL PL15701577T patent/PL3097086T3/pl unknown
- 2015-01-23 SI SI201530170T patent/SI3097086T1/en unknown
- 2015-01-23 PE PE2016001236A patent/PE20161218A1/es unknown
- 2015-01-23 AU AU2015208932A patent/AU2015208932C1/en active Active
- 2015-01-23 AR ARP150100202A patent/AR099177A1/es active IP Right Grant
- 2015-01-23 MX MX2016009349A patent/MX368840B/es active IP Right Grant
- 2015-01-23 NZ NZ734768A patent/NZ734768A/en unknown
- 2015-01-23 HU HUE20173862A patent/HUE070606T2/hu unknown
- 2015-01-23 LT LTEP15701577.7T patent/LT3097086T/lt unknown
- 2015-01-23 CA CA2935625A patent/CA2935625C/en active Active
- 2015-01-23 PT PT157015777T patent/PT3097086T/pt unknown
- 2015-01-23 EA EA201691375A patent/EA032794B1/ru unknown
- 2015-01-23 ES ES15701577.7T patent/ES2658516T3/es active Active
- 2015-01-23 PL PL17195612T patent/PL3323814T3/pl unknown
- 2015-01-23 WO PCT/GB2015/050155 patent/WO2015110826A1/en not_active Ceased
2016
- 2016-07-05 IL IL246614A patent/IL246614B/en active IP Right Grant
- 2016-07-13 DO DO2016000175A patent/DOP2016000175A/es unknown
- 2016-07-20 PH PH12016501439A patent/PH12016501439B1/en unknown
- 2016-07-25 CL CL2016001889A patent/CL2016001889A1/es unknown
- 2016-08-23 ZA ZA2016/05856A patent/ZA201605856B/en unknown
- 2016-11-08 US US15/346,411 patent/US9815805B2/en active Active
2017
- 2017-01-18 AU AU2017200338A patent/AU2017200338B2/en active Active
- 2017-06-11 IL IL252836A patent/IL252836A0/en active IP Right Grant
- 2017-09-19 US US15/708,634 patent/US10287258B2/en active Active
2018
- 2018-01-22 ZA ZA2018/00431A patent/ZA201800431B/en unknown
- 2018-02-05 CY CY20181100132T patent/CY1120049T1/el unknown
- 2018-04-30 AU AU2018202956A patent/AU2018202956B2/en active Active
2019
- 2019-01-16 JP JP2019005300A patent/JP6804570B2/ja active Active
- 2019-03-19 US US16/358,091 patent/US10669245B2/en active Active
- 2019-03-25 IL IL265611A patent/IL265611A/en unknown
- 2019-04-17 AU AU2019202675A patent/AU2019202675B2/en active Active
2020
- 2020-04-22 US US16/855,522 patent/US11117874B2/en active Active
- 2020-07-23 HR HRP20201147TT patent/HRP20201147T1/hr unknown
- 2020-07-23 CY CY20201100674T patent/CY1123391T1/el unknown
- 2020-12-02 JP JP2020200413A patent/JP7157791B2/ja active Active
2021
- 2021-02-08 US US17/170,641 patent/US11667615B2/en active Active
2022
- 2022-04-04 JP JP2022062548A patent/JP7336563B2/ja active Active
- 2022-09-09 US US17/942,106 patent/US11655221B2/en active Active
- 2022-09-09 US US17/942,111 patent/US11773069B2/en active Active
- 2022-09-10 US US17/942,120 patent/US11655222B2/en active Active
- 2022-09-10 US US17/942,121 patent/US11655223B2/en active Active
- 2022-09-10 US US17/942,122 patent/US11655224B2/en active Active
- 2022-09-10 US US17/942,123 patent/US11814359B2/en active Active
- 2022-09-10 US US17/942,112 patent/US11673871B2/en active Active
- 2022-09-15 US US17/946,024 patent/US11680049B2/en active Active
- 2022-09-16 US US17/946,112 patent/US11673872B2/en active Active
2023
- 2023-04-13 US US18/300,350 patent/US20230250071A1/en not_active Abandoned
- 2023-08-21 JP JP2023133935A patent/JP7628587B2/ja active Active
- 2023-12-08 US US18/533,894 patent/US12054465B2/en active Active
2024
- 2024-06-17 US US18/745,710 patent/US20240336582A1/en not_active Abandoned
2025
- 2025-01-29 JP JP2025012602A patent/JP7714823B2/ja active Active
- 2025-07-16 JP JP2025119347A patent/JP2025157389A/ja active Pending

Also Published As

Publication number	Publication date
PE20161218A1 (es)	2016-11-27
AU2019202675A1 (en)	2019-05-16
US20230062646A1 (en)	2023-03-02
EP4548972A3 (en)	2025-06-25
CL2016001889A1 (es)	2016-12-09
US11667615B2 (en)	2023-06-06
CN105980367A (zh)	2016-09-28
US20230025351A1 (en)	2023-01-26
JP2022096662A (ja)	2022-06-29
HRP20250302T1 (hr)	2025-04-25
DOP2016000175A (es)	2016-08-15
US10287258B2 (en)	2019-05-14
PT3323814T (pt)	2020-08-05
JP2021046423A (ja)	2021-03-25
US12054465B2 (en)	2024-08-06
US20230278969A1 (en)	2023-09-07
SG10201701056QA (en)	2017-03-30
AU2015208932B8 (en)	2017-03-09
AU2017200338A1 (en)	2017-02-02
EP3744714A1 (en)	2020-12-02
KR20160111470A (ko)	2016-09-26
MX2016009349A (es)	2016-10-13
JP2025157389A (ja)	2025-10-15
US11673871B2 (en)	2023-06-13
JP2019070029A (ja)	2019-05-09
PL3744714T3 (pl)	2025-09-08
HK1255870A1 (en)	2019-08-30
MX368840B (es)	2019-10-18
AP2016009322A0 (en)	2016-07-31
JP7336563B2 (ja)	2023-08-31
TWI690517B (zh)	2020-04-11
NZ734768A (en)	2022-09-30
RS66709B1 (sr)	2025-05-30
EA032794B1 (ru)	2019-07-31
CA2935625C (en)	2022-10-18
HUE070606T2 (hu)	2025-06-28
US11814359B2 (en)	2023-11-14
US20230085620A1 (en)	2023-03-23
SI3323814T1 (sl)	2020-10-30
AR099177A1 (es)	2016-07-06
JP2023156479A (ja)	2023-10-24
NO2699580T3 (da)	2018-02-24
CY1120049T1 (el)	2018-12-12
US11655223B2 (en)	2023-05-23
US11655222B2 (en)	2023-05-23
US20200247765A1 (en)	2020-08-06
RS60639B1 (sr)	2020-09-30
HUE038274T2 (hu)	2018-10-29
EP3097086B1 (en)	2017-12-13
AU2018202956A1 (en)	2018-05-17
RS56919B1 (sr)	2018-05-31
US20170057938A1 (en)	2017-03-02
CN110483492A (zh)	2019-11-22
SG11201606052TA (en)	2016-08-30
US20240336582A1 (en)	2024-10-10
ES2808060T3 (es)	2021-02-25
FI3744714T3 (fi)	2025-04-01
US20230250071A1 (en)	2023-08-10
US11655224B2 (en)	2023-05-23
UY35963A (es)	2015-07-31
JP6804570B2 (ja)	2020-12-23
US11117874B2 (en)	2021-09-14
AU2017200338B2 (en)	2018-03-01
JP7628587B2 (ja)	2025-02-10
SMT201800058T1 (it)	2018-03-08
PH12016501439A1 (en)	2017-02-06
DK3097086T3 (da)	2018-02-05
US20230033573A1 (en)	2023-02-02
JP2017503832A (ja)	2017-02-02
NZ722063A (en)	2017-09-29
ES3018635T3 (es)	2025-05-16
JP7714823B2 (ja)	2025-07-29
LT3323814T (lt)	2020-10-26
SMT202000433T1 (it)	2020-09-10
US20230116721A1 (en)	2023-04-13
KR102417684B1 (ko)	2022-07-05
IL265611A (en)	2019-05-30
US20240132455A1 (en)	2024-04-25
US20230115170A1 (en)	2023-04-13
MY194850A (en)	2022-12-19
HUE052421T2 (hu)	2021-04-28
ZA201605856B (en)	2020-02-26
AU2015208932B2 (en)	2017-02-16
LT3744714T (lt)	2025-04-10
JP2025072423A (ja)	2025-05-09
AU2015208932C1 (en)	2017-05-25
US10669245B2 (en)	2020-06-02
ES2658516T3 (es)	2018-03-12
EP4548972A2 (en)	2025-05-07
EP3097086A1 (en)	2016-11-30
EP3323814B1 (en)	2020-05-13
HK1225730B (en)	2017-09-15
SI3744714T1 (sl)	2025-05-30
US11655221B2 (en)	2023-05-23
SI3097086T1 (en)	2018-04-30
PH12016501439B1 (en)	2017-02-06
DK3744714T3 (da)	2025-04-07
CA2935625A1 (en)	2015-07-30
CN105980367B (zh)	2019-08-23
JP7157791B2 (ja)	2022-10-20
US20210238152A1 (en)	2021-08-05
AU2019202675B2 (en)	2020-05-28
HRP20201147T1 (hr)	2020-12-11
PL3097086T3 (pl)	2018-04-30
WO2015110826A1 (en)	2015-07-30
US20180251436A1 (en)	2018-09-06
SMT202500137T1 (it)	2025-05-12
CY1123391T1 (el)	2021-12-31
PT3097086T (pt)	2018-02-21
US11773069B2 (en)	2023-10-03
JP6469711B2 (ja)	2019-02-13
BR112016016224B1 (pt)	2023-02-23
US20200017455A1 (en)	2020-01-16
US9522894B2 (en)	2016-12-20
PL3323814T3 (pl)	2020-10-19
PT3744714T (pt)	2025-04-07
US11673872B2 (en)	2023-06-13
AU2015208932A1 (en)	2016-07-28
LT3097086T (lt)	2018-02-26
CN110483492B (zh)	2023-07-21
HRP20180116T1 (hr)	2018-03-23
US9815805B2 (en)	2017-11-14
US20230028726A1 (en)	2023-01-26
AU2018202956B2 (en)	2019-05-09
EP3323814A1 (en)	2018-05-23
TW201612167A (en)	2016-04-01
IL252836A0 (en)	2017-08-31
CR20160327A (es)	2016-10-20
ZA201800431B (en)	2019-09-25
US11680049B2 (en)	2023-06-20
BR112016016224A2 (da)	2017-08-08
US20230069044A1 (en)	2023-03-02
EP3744714B1 (en)	2025-01-15
EA201691375A1 (ru)	2017-01-30
IL246614B (en)	2018-02-28
US20150210655A1 (en)	2015-07-30
AU2015208932A8 (en)	2017-03-09

Publication	Publication Date	Title
DK3323814T3 (da)	2020-08-03	(2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepan-2-carboxamider som dipeptidylpeptidase i-hæmmere
LT3105226T (lt)	2019-11-11	Ciklopropilaminai, kaip lsd1 inhibitoriai
DK3105218T3 (da)	2019-11-04	Cyclopropylaminer som lsd1-inhibitorer
DK3461821T3 (da)	2020-08-17	Indolcarboxamidforbindelser, der er brugbar som kinasehæmmere
IL261904A (en)	2018-10-31	6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists
DK3371190T3 (da)	2022-05-23	Heterocykliske forbindelser som pi3k-gamma-inhibitorer
BR112017012364A2 (pt)	2018-04-24	pré-tratamento rápido.
DK3458460T3 (da)	2021-03-01	Imidazoler som histondemethylase-inhibitorer
DK3352817T3 (da)	2021-06-28	Injektionsapparat, navnlig som auto-injektor
ES1140983Y (es)	2015-09-30	Maquina de embalaje de termoconformado
LT3233862T (lt)	2019-09-10	Imidazopiridazino dariniai, kaip pi3kbeta slopikliai
DK3123576T3 (da)	2021-06-14	Modul, spesielt et industrielt modul
DK3233839T3 (da)	2019-12-09	Heterocyclylkoblede imidazopyridazinderivater som pi3k-beta-inhibitorer
DK3237407T3 (da)	2020-07-20	3,5-diaminopyrazolkinasehæmmere
ITRM20150057U1 (it)	2016-11-11	Imballaggio per articoli.
LT3110812T (lt)	2019-07-10	Anti-amiloidų junginiai, turintys benzofurazano
UA29878S (uk)	2015-07-27	Упаковка для зубочисток
TH1601002634B (th)	2017-08-24	เครื่องติดฉลาก
UA28920S (uk)	2015-02-25	Пакет
TH1501005075A (th)	2017-03-09	สารผสมการบ่ม-ความชื้นประเภทหนึ่งห่อ
BR302014000338S1 (pt)	2014-09-16	Configuração aplicada em garrafa.
BR302014000025S1 (pt)	2014-09-16	Configuração aplicada em frasco.
ITRM20140098U1 (it)	2015-12-19	Macchina utensile.